Edwards Lifesciences Intrinsic Value Calculation – EDWARDS LIFESCIENCES Reports Record Earnings for Q2 FY2023
August 1, 2023
🌥️Earnings Overview
EDWARDS LIFESCIENCES ($NYSE:EW) announced their earnings results for the second quarter of their fiscal year 2023 which ended on June 30, 2023. Total revenue for Q2 came in at USD 1530.2 million, a growth of 11.4% year-over-year. Unfortunately, net income was reported to be USD 307.1 million, a decrease of 24.4% compared to the same period last year.
Stock Price
On Wednesday, EDWARDS LIFESCIENCES reported record earnings for Q2 FY2023. The company’s stock opened at $91.3 and closed at $91.6, a slight decrease of 0.1% from the previous closing price of 91.7. The company attributes its success to its healthcare solutions, which are designed to improve patient outcomes. EDWARDS LIFESCIENCES has continued to focus on developing innovative technologies that enable healthcare providers to focus on delivering the best quality care to their patients.
Additionally, the company has made several strategic investments and acquisitions to expand their product portfolio and increase their market reach. Overall, EDWARDS LIFESCIENCES reported strong financial results for Q2 despite the slight decrease in stock prices. The company’s commitment to helping healthcare professionals optimize patient care will continue to bring sustainable growth in the coming quarters. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Edwards Lifesciences. More…
| Total Revenues | Net Income | Net Margin |
| 5.66k | 1.39k | 27.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Edwards Lifesciences. More…
| Operations | Investing | Financing |
| 1.24k | 252.3 | -1.58k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Edwards Lifesciences. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 9k | 2.56k | 10.52 |
Key Ratios Snapshot
Some of the financial key ratios for Edwards Lifesciences are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 9.4% | 12.7% | 31.5% |
| FCF Margin | ROE | ROA |
| 17.4% | 18.0% | 12.4% |
Analysis – Edwards Lifesciences Intrinsic Value Calculation
GoodWhale’s analysis of EDWARDS LIFESCIENCES‘ fundamentals shows that the intrinsic value of its share is around $106.3 according to our proprietary Valuation Line. This intrinsic value is determined by evaluating a wide range of financial metrics, including the company’s performance, liquidity, leverage, and growth potential. Currently, EDWARDS LIFESCIENCES’ stock is trading at $91.6 – significantly below the intrinsic value of $106.3. This suggests that the stock is currently undervalued by 13.8%. As such, this could be a good opportunity to invest in EDWARDS LIFESCIENCES for long-term growth. More…
Peers
Edwards Lifesciences Corp is a global leader in the development of products and technologies to treat cardiovascular disease. The company’s products are used by healthcare professionals to treat patients suffering from cardiac and vascular diseases. Edwards Lifesciences Corp’s competitors include Implanet SA, Avra Medical Robotics Inc, and Paragon 28 Inc.
– Implanet SA ($OTCPK:IMPZY)
Implanet SA is an orthopedic company that manufactures and distributes medical devices. The company has a market cap of 3.76M as of 2022 and a Return on Equity of -114.56%. The company’s products are used in the treatment of conditions such as osteoarthritis, degenerative disc disease, and deformities of the spine and extremities.
– Avra Medical Robotics Inc ($OTCPK:AVMR)
Avra Medical Robotics Inc is a publicly traded company with a market capitalization of 239.1 thousand dollars as of 2022. The company focuses on the development and commercialization of robotic technologies for use in minimally invasive surgery. The company’s primary product is the Avra Surgical System, a surgical robotics platform that assists surgeons in performing tasks such as suturing, tissue manipulation, and vessel sealing. The company has received FDA clearance for the Avra Surgical System and has CE Mark approval for the European Union.
– Paragon 28 Inc ($NYSE:FNA)
Paragon 28 Inc is a publicly traded company with a market capitalization of 1.33 billion as of 2022. The company has a negative return on equity of 9.25%. Paragon 28 Inc is engaged in the business of providing turnkey engineering, procurement and construction services to the oil and gas industry.
Summary
The performance of Edwards Lifesciences in the second quarter of its fiscal year 2023 (ending June 30th) demonstrated a mixed performance. Total revenue increased by 11.4% year-over-year, while net income decreased by 24.4%. Investors should consider the factors that drove these figures to gain more insight into the company’s performance and determine the potential return on investment. A thorough analysis should also consider the company’s competitive landscape, market trends, and macroeconomic environment to gain a better understanding of the outlook for Edwards Lifesciences.
